Key facts
- Rakuten Medical’s last known valuation is $818.0M (Mar 2024).
- It has raised $887.1M across 11 recorded rounds; the latest was Later Stage VC ($111.5M) in Jul 2025.
- Notable investors include General Catalyst, Mizuho Bank, Rakuten Capital, ABC Partners, Abies Capital — 19 tracked in total.
- Rakuten Medical has filed 12 Form Ds with the SEC since 2019, most recently May 2025 ($1.9M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 11 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Rakuten Medical
Funding rounds
11 roundsAbout Rakuten Medical
Developer of precision-targeted cancer therapies designed to treat solid tumors. The company's therapies consist of a cancer-targeting monoclonal antibody conjugated to a photoactivatable molecule to gain anticancer activity upon light-mediated activation at the tumor site, enabling patients with recurrent head and neck cancer to access oncologic drugs that permit rapid cancer cell killing without damage to the surrounding healthy tissues.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2010
- Employees
- 126
- Website
- rakuten-med.com/
- Ownership
- Privately Held (backing)
Rakuten Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rakuten Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rakuten Medical in its N-PORT filings yet. We sweep new filings monthly.